CRTX [NASD]
Cortexyme, Inc.
Index- P/E- EPS (ttm)-2.96 Insider Own2.80% Shs Outstand30.13M Perf Week-1.79%
Market Cap98.90M Forward P/E- EPS next Y-1.95 Insider Trans0.00% Shs Float22.43M Perf Month-19.90%
Income-88.50M PEG- EPS next Q-0.55 Inst Own65.30% Short Float25.57% Perf Quarter-30.23%
Sales- P/S- EPS this Y-14.90% Inst Trans2.97% Short Ratio12.69 Perf Half Y-76.43%
Book/sh3.53 P/B0.93 EPS next Y10.60% ROA-63.40% Target Price50.79 Perf Year-90.93%
Cash/sh3.06 P/C1.08 EPS next 5Y18.30% ROE-70.80% 52W Range3.00 - 121.98 Perf YTD-73.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-97.32% Beta-
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low9.00% ATR0.36
Employees55 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)36.01 Volatility9.83% 9.80%
OptionableYes Debt/Eq0.00 EPS Q/Q8.10% Profit Margin- Rel Volume0.73 Prev Close3.30
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume451.81K Price3.27
Recom2.90 SMA20-8.25% SMA50-30.71% SMA200-89.50% Volume73,668 Change-0.91%
Jan-28-22Downgrade Canaccord Genuity Buy → Hold $75 → $12
Jan-27-22Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-27-21Downgrade BofA Securities Neutral → Underperform $58 → $15
Apr-26-21Resumed Credit Suisse Underperform $14
Feb-17-21Downgrade Jefferies Buy → Hold $59 → $34
Dec-11-20Initiated Citigroup Sell $20
Jun-24-20Initiated H.C. Wainwright Buy $76
Jun-02-20Initiated Jefferies Buy $59
Jun-03-19Initiated JMP Securities Mkt Outperform $53
Jun-03-19Initiated Credit Suisse Underperform $14
Jun-03-19Initiated Canaccord Genuity Buy $42
Jun-03-19Initiated BofA/Merrill Neutral $28
May-20-22 08:01AM  
08:00AM  
May-12-22 08:00AM  
May-10-22 08:00AM  
May-06-22 11:19AM  
May-03-22 09:56AM  
Mar-21-22 08:00AM  
Mar-15-22 08:00AM  
Mar-14-22 08:00AM  
Mar-09-22 08:00AM  
Mar-08-22 11:27AM  
08:00AM  
Feb-24-22 03:49PM  
Feb-18-22 10:00AM  
Feb-03-22 03:03PM  
Feb-02-22 10:00AM  
Feb-01-22 05:16PM  
11:36AM  
09:38AM  
08:01AM  
08:00AM  
Jan-26-22 01:25PM  
09:13AM  
08:00AM  
Jan-25-22 05:38PM  
Jan-12-22 10:00AM  
Jan-07-22 03:21PM  
Jan-04-22 05:03AM  
Dec-17-21 01:50PM  
Dec-09-21 10:00AM  
Dec-01-21 09:01AM  
Nov-23-21 08:00AM  
Nov-11-21 04:08PM  
12:54PM  
11:30AM  
10:08AM  
Nov-05-21 08:16AM  
Nov-04-21 08:00AM  
04:33AM  
02:39AM  
Nov-03-21 11:15AM  
Nov-01-21 03:21PM  
Oct-29-21 06:23PM  
05:08PM  
Oct-28-21 10:00AM  
05:25AM  
04:50AM  
Oct-27-21 10:50PM  
04:05PM  
02:40PM  
01:55PM  
12:43PM  
12:14PM  
12:00PM  
12:00PM  
11:18AM  
10:21AM  
10:20AM  
07:09AM  
Oct-26-21 04:01PM  
04:00PM  
Oct-21-21 11:00AM  
Oct-08-21 11:57AM  
Sep-27-21 08:00AM  
Sep-08-21 08:00AM  
Sep-07-21 08:00AM  
Aug-25-21 08:00AM  
Aug-18-21 08:00AM  
Aug-09-21 08:00AM  
Aug-07-21 05:29AM  
Aug-04-21 08:00AM  
Jul-26-21 09:05AM  
Jul-23-21 08:00AM  
Jul-22-21 08:00AM  
Jul-21-21 08:00AM  
Jul-19-21 08:00AM  
Jul-08-21 08:00AM  
Jun-13-21 02:20PM  
Jun-01-21 08:00AM  
May-26-21 08:00AM  
May-10-21 08:00AM  
May-09-21 04:13AM  
May-04-21 08:00AM  
Mar-25-21 08:00AM  
Mar-21-21 09:52PM  
Mar-18-21 08:01PM  
Mar-16-21 10:00PM  
Mar-12-21 06:15AM  
Mar-10-21 08:00AM  
Mar-09-21 10:45PM  
Mar-08-21 08:00AM  
Mar-07-21 05:53PM  
Mar-03-21 03:00AM  
Feb-22-21 01:10PM  
Feb-20-21 07:00PM  
Feb-18-21 09:47PM  
04:45PM  
Feb-17-21 11:38AM  
Feb-16-21 08:52AM  
Feb-15-21 09:13PM  
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lynch CaseyChief Executive OfficerNov 18Option Exercise0.4660,00027,600109,895Nov 19 08:58 PM
LOWE CHRISTOPHER P.COO & Chief Financial OfficerNov 16Option Exercise2.2330,00066,90090,000Nov 16 08:17 PM
Dominy Stephen S.Chief Scientific OfficerNov 12Buy14.4076310,9871,217,086Nov 12 06:47 PM
McLoughlin MargaretDirectorOct 08Option Exercise17.001,00017,0001,000Oct 12 05:48 PM
McLoughlin MargaretDirectorOct 08Sale88.931,00088,9300Oct 12 05:48 PM
LOWE CHRISTOPHER P.COO & Chief Financial OfficerOct 05Option Exercise54.854,963272,22164,963Oct 07 06:24 PM
LOWE CHRISTOPHER P.COO & Chief Financial OfficerOct 05Sale98.504,963488,85660,000Oct 07 06:24 PM
LOWE CHRISTOPHER P.COO & Chief Financial OfficerAug 17Option Exercise2.2330,00066,90060,000Aug 18 05:25 PM
McLoughlin MargaretDirectorAug 16Option Exercise17.006,000102,0006,000Aug 18 05:30 PM
LOWE CHRISTOPHER P.COO & Chief Financial OfficerAug 16Option Exercise2.2322,00049,06052,000Aug 18 05:25 PM
McLoughlin MargaretDirectorAug 16Sale95.446,000572,6440Aug 18 05:30 PM
LOWE CHRISTOPHER P.COO & Chief Financial OfficerAug 16Sale95.3122,0002,096,77930,000Aug 18 05:25 PM
Detke Michael J.Chief Medical OfficerAug 10Option Exercise2.2310,00022,30010,000Aug 12 05:37 PM
Detke Michael J.Chief Medical OfficerAug 10Sale100.0010,0001,000,0000Aug 12 05:37 PM
Detke Michael J.Chief Medical OfficerJul 07Option Exercise2.2317,40038,80217,400Jul 07 08:38 PM
Detke Michael J.Chief Medical OfficerJul 07Sale55.2017,400960,5490Jul 07 08:38 PM
Detke Michael J.Chief Medical OfficerJul 06Option Exercise2.2312,60028,09840,861Jul 07 08:38 PM
Detke Michael J.Chief Medical OfficerJul 06Sale53.5440,8612,187,6230Jul 07 08:38 PM
McLoughlin MargaretDirectorJun 28Sale55.1555030,3320Jun 29 05:26 PM